Monika T. K.
- Country
- Slovakia
- Department
- Neurologická klinika
Research Overview
- Randomized, Quadruple-Blind, Placebo-Controlled Phase 2b Study of Batoclimab in Adults with Active Chronic Inflammatory Demyelinating Polyneuropathy
- Phase 3 Randomized Double-Blind Study of Empasiprubart vs. Human Normal Immunoglobulin (IV) in Adults with Multifocal Motor Neuropathy
- A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
Data & Insights
Has run more than one trial at 36 of 128 partner sites.
Specializations
Neurological Disorders
The investigator specializes in the study and treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), focusing on innovative therapeutic approaches for this rare neurological condition.
- Autoimmune neuropathies
- Inflammatory nerve disorders
- Demyelinating diseases
Active in evaluating novel therapeutic agents for managing chronic inflammatory neurological conditions.
Immunological Therapeutics
Concentrates on immunological treatment modalities including immunoglobulin therapy administration and plasma exchange procedures for neurological disorders.
- Immunoglobulin therapy
- Plasma exchange treatments
- Novel immunological agents
Explores various treatment delivery methods including intravenous and subcutaneous administration routes.
Clinical Assessment
Implements sophisticated clinical evaluation methods including the Inflammatory Neuropathy Cause and Treatment (INCAT) scoring system for assessing treatment efficacy.
- Neurological assessment tools
- Treatment response evaluation
- Clinical outcome measures
Utilizes advanced clinical metrics to monitor disease progression and therapeutic effectiveness.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.